CVS and Walgreens plan to start dispensing abortion pill mifepristone soon

Date:

Share post:


The drugstore chains CVS Health and Walgreens plan to start dispensing an abortion pill in a few states within weeks.

CVS Health will start filling prescriptions for mifepristone in Rhode Island and neighboring Massachusetts “in the weeks ahead,” spokeswoman Amy Thibault said Friday.

Walgreens will begin dispensing the medication within a week, spokesman Fraser Engerman said. The chain will start with some locations in New York, Pennsylvania, Massachusetts, California and Illinois.

He said the company was starting in “in select locations to allow us to ensure quality, safety and privacy for our patients, providers and team members.”

Thibault said CVS Health will add states “where allowed by law, on a rolling basis.”

The New York Times first reported the retailers’ plans.

CVS Health Corp., the nation’s largest drugstore chain, runs nearly 9,400 locations. Walgreens Boots Alliance Inc. has about 8,700 U.S. stores.

Their announcements Friday marked “an important milestone” in ensuring mifepristone access, President Joe Biden said in a statement. He noted that many women will soon be able to pick up their prescriptions at a local, certified pharmacy like they would any other medication.

“I encourage all pharmacies that want to pursue this option to seek certification,” he said.

The moves by CVS and Walgreens come more than a year after the U.S. Food and Drug Administration finalized a rule change that broadened availability of abortion pills to many more pharmacies, including large chains and mail-order companies.

The FDA in 2000 approved mifepristone to terminate pregnancies of up to 10 weeks, when used with a second drug, misoprostol.

Mifepristone is taken first to dilate the cervix and block the hormone progesterone, which is needed to sustain a pregnancy. Misoprostol is taken 24 to 48 hours later, causing the uterus to contract and expel pregnancy tissue.

For more than 20 years, the FDA labeling had limited dispensing to a subset of specialty offices and clinics, due to safety concerns.

The U.S. Supreme Court is weighing a challenge from conservative groups who are seeking to reverse mifepristone’s approval or roll back policies that have made it easier to obtain.

___

The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Science and Educational Media Group. The AP is solely responsible for all content.



Source link

Lisa Holden
Lisa Holden
Lisa Holden is a news writer for LinkDaddy News. She writes health, sport, tech, and more. Some of her favorite topics include the latest trends in fitness and wellness, the best ways to use technology to improve your life, and the latest developments in medical research.

Recent posts

Related articles

Judge dismisses Meta shareholder lawsuit claiming that directors' obligations extend beyond company

DOVER, Del. -- A Delaware judge on Tuesday dismissed a shareholder lawsuit asserting novel claims about the...

Delaware judge refuses to fast-track certain claims in post-merger lawsuit against Trump Media

A Delaware judge has granted a request by attorneys for Donald Trump and Trump Media & Technology...

US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition

WASHINGTON -- Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection...

The USDA is testing ground beef for bird flu. Experts are confident the meat supply is safe

FILE - Ground beef is displayed for sale at a market in Washington, Saturday, April 1, 2017....

Fired Google workers ousted over Israeli contract protests file complaint with labor regulators

The Google sign is displayed outside the Google offices in Sunnyvale, Calif., on Thursday, April 18, 2024....

US drug control agency will move to reclassify marijuana in a historic shift, AP sources say

WASHINGTON -- WASHINGTON (AP) — The U.S. Drug Enforcement Administration will move to reclassify marijuana as a...

G7 nations commit to phasing out coal by 2035 but give Japan some flexibility

MILAN -- Energy and environment ministers of the Group of Seven leading industrialized nations committed Tuesday to...

Lilly rides Mounjaro, Zepbound to better-than-expected 1Q profit despite supply issues

Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli...